Results 101 to 110 of about 130,157 (357)
The peptide AVFQHNCQE demonstrated to produce nitric oxide-mediated antihypertensive effect. This study investigates the bioavailability and the opioid-like activity of this peptide after its oral administration.
Anna Mas-Capdevila+5 more
doaj +1 more source
Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders [PDF]
Alcohol use disorders (AUDs) cause serious problems in society and few effective treatments are available. Caenorhabditis elegans (C. elegans) is an excellent invertebrate model to study the neurobiological basis of human behavior with a conserved, fully
Bell, Richard L.+6 more
core +1 more source
Molecular Aspects of Opioid Receptors and Opioid Receptor Painkillers
The unpleasant sensation of pain is experienced by all human beings at a given point in life. When pain gets severe and/or chronic it requires medical treatment. For over a thousand years, opioid agonists have been employed therapeutically to treat pain, with the first reports of such use involving the alkaloid morphine dated to the second century B.C.(
Austin B. Yongye+1 more
openaire +4 more sources
GRKs as Key Modulators of Opioid Receptor Function
Understanding the link between agonist-induced phosphorylation of the mu-opioid receptor (MOR) and the associated physiological effects is critical for the development of novel analgesic drugs and is particularly important for understanding the ...
Laura Lemel+2 more
doaj +1 more source
Aims To develop an evidence‐ and consensus‐based patient prioritization tool for use by UK mental health inpatient pharmacy teams. Methods A modified‐Delphi technique was used to obtain experts' agreement on the content, design and practical use of the patient prioritization tool.
Fatima Q. Alshaikhmubarak+3 more
wiley +1 more source
Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. [PDF]
The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects.
Livingston, Kathryn E+4 more
core
Pharmacogenetics of analgesic drugs [PDF]
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R+4 more
core +1 more source
Aims We sought to characterize adverse events and deaths associated with the use of psychoactive substances in children and adolescents. Methods Two French Addictovigilance databases were analysed: spontaneous reports and deaths over the period 2016–2021, in subjects aged 10–<18 years. An unsupervised classification was implemented on consumption data (
Hélène Peyrière+13 more
wiley +1 more source
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]
RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano+33 more
core +1 more source
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies
The opioid system consists of three receptors, mu, delta, and kappa, which are activated by endogenous opioid peptides (enkephalins, endorphins and dynorphins). The endogenous cannabinoid system comprises lipid neuromodulators (endocannabinoids), enzymes
Katia eBefort
doaj +1 more source